Start the conversation
We've had some queries about TrovaGene Inc. (Nasdaq: TROV) after shares of our "Liquid Biopsy" recommendation rose five days in a row - an advance that took the shares up nearly 45% over those five trading sessions.
And though we predicted this - and have devoted quite a bit of analysis to this stock of late - we're always glad to respond to inquiries... especially when it comes to a stock like this one that we believe offers a massive possible upside.
This will be a relatively short update.
And we'll start with the facts.
This is premium content for Private Briefing subscribers only.